Modelling & Simulation SIG

The Modelling and Simulation Special Interest Group is a forum to share knowledge and understanding about statistical modelling and simulation related to pharmaceutical development.

Publications:

  • Predictive event modelling in multicenter clinical trials with waiting time to response, Vladimir V. Anisimov DOI: 10.1002/pst.525 Pharmaceutical Statistics Special Issue: Focusing on the PSI Special Interest Groups Volume 10, Issue 6, pages 517–522, November/December 2011
  • Modelling and simulation in the pharmaceutical industry—some reflections, Carl-Fredrik Burman, Stig Johan Wiklund DOI: 10.1002/pst.523 Pharmaceutical Statistics Special Issue: Focusing on the PSI Special Interest Groups Volume 10, Issue 6, pages 508–516, November/December 2011
  • V. Anisimov, Effects of unstratified and centre-stratified randomization in multicentre clinical trials, Pharmaceutical Statistics, v. 10, iss. 1, 2011, pp. 50-59.
  • V. Anisimov, Drug supply modeling in clinical trials (statistical methodology), Pharmaceutical Outsourcing, May/June, 2010, pp. 50-55.
  • V. Anisimov, Predictive modelling of recruitment and drug supply in multicenter clinical trials, Proc. of the Joint Statistical Meeting, Washington, USA, August, 2009, pp. 1248-1259.
  • V. Anisimov, Recruitment modeling and predicting in clinical trials, Pharmaceutical Outsourcing, March/April 2009, Vol. 10, Issue 1, pp. 44-48.
  • V. Anisimov, Effects of unstratified and centre-stratified randomization in multicentre clinical trials, Pharmaceutical Statistics v.10, iss. 1, 2011, pp.50-59
  • V. Anisimov, Impact of stratified randomization in clinical trials, In: Giovagnoli A., Atkinson AC., Torsney B. (Eds), MODA 9 - Advances in Model-Oriented Design and Analysis. Physica-Verlag/Springer, Berlin, 2010, pp. 1-8.
  • S. Senn, V. Anisimov, V. Fedorov, Comparisons of minimisation and Atkinson's algorithm, Statistics in Medicine, 2010, V. 29, issue 7/8, pp. 721-730.
  • V. Anisimov, V. Fedorov, Modeling, prediction and adaptive adjustment of recruitment in multicentre trials, Statistics in Medicine, v. 26, No 27, 2007, pp. 4958-4975.

Coming soon:

Autumn 2014 - Making Modelling and Simulation Work for Regulators and Industry: This one day meeting will be a forum for examining how industry can best present our model-derived predictions to regulators.

External Links:

Recent Activity

Latest News


Show all news

EventsFuture Events


  • Expert Working Group on Confidentiality of Interim Results - Dates: 11 May, 2017

    The PSI/EFSPI expert working group on Confidentiality of Interim Results are planning to meet face to face on 11 May.
  • Estimating Sample Sizes in Clinical Trials - Dates: 28 – 29 Jun, 2017

    The three most important aspects of a clinical trial are: design, design and design. A sample size estimate is just one aspect of a clinical study design. The course describes calculations for sample size estimation in the design of clinical trials. It will be highlighted how the objectives of a clinical trial will impact on sample size calculations. The course is a practical course and all methods will be illustrated with examples and case studies.
Leeds-80x250

Medical Statistician / Senior Medical Statistician

read more...

GSK logo

Director, Statistics

read more...

Astrazeneca

Associate Director, Statistics Team leader - Early Clinical Development

read more...

Astrazeneca

Early Clinical Development – various levels

read more...

LOGO

Biostatistics Head of Department

read more...

Astrazeneca

Principal Statistician – Centralised Statistical Monitoring

read more...

Astrazeneca

Clinical Trial Design Methodology Expert - Statistical Innovation Team

read more...